NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Price, News & Analysis $0.10 0.00 (-0.99%) As of 03:22 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOptions ChainSEC FilingsTrendsBuy This Stock About Galera Therapeutics Stock (NASDAQ:GRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Galera Therapeutics alerts:Sign Up Key Stats Today's Range$0.10▼$0.1050-Day Range$0.04▼$0.1052-Week Range$0.02▼$0.15Volume2,590 shsAverage Volume206,149 shsMarket Capitalization$16.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Galera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company focuses on developing precision medicines designed to address oxidative stress and inflammation in pulmonary and rare diseases. Galera’s proprietary platform centers on small-molecule prodrugs of glutathione and related thiol compounds intended to enhance intracellular antioxidant defenses. Galera’s lead product candidate is an inhaled glutathione prodrug currently in early-stage clinical trials for acute lung injury and acute respiratory distress syndrome. In addition to its pulmonary programs, the company is advancing research into supportive therapies for oncology patients and exploring additional indications where modulation of oxidative stress may offer therapeutic benefit. Galera employs both inhalation and systemic delivery approaches to optimize tissue targeting and pharmacokinetics. Founded in 2013, Galera has secured funding through private financings and a public listing on the NASDAQ under the symbol GRTX. The company collaborates with academic research centers and clinical investigators in the United States, and it is positioning itself for potential international partnerships to expand development and commercialization efforts. Under the guidance of a team of seasoned biotechnology executives and drug development scientists, Galera aims to translate its redox-modulating platform into new treatments for patients with high-unmet-need respiratory and systemic conditions.AI Generated. May Contain Errors. Read More Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRTX Stock News HeadlinesGalera Therapeutics Inc.May 19, 2026 | marketwatch.comGalera Therapeutics Eliminates Series B Preferred, Simplifies EquityMay 19, 2026 | tipranks.comSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their historic runs - says the SpaceX IPO is set for June 12 and could be the most anticipated market debut ever. Brown is showing investors how to legally claim a stake before the company goes public, ahead of what chief market strategist Shay Boloor called 'the craziest IPO in the history of the stock market.'June 4 at 1:00 AM | Brownstone Research (Ad)Malvern-based Galera Therapeutics to be acquired in reverse mergerApril 16, 2026 | msn.comGalera Therapeutics to be acquired by Cambridge biotech firmApril 15, 2026 | bizjournals.comGRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersApril 14, 2026 | businesswire.comObsidian Therapeutics and Galera Therapeutics Announce Merger to Advance Engineered TIL Cell Therapies and Secure $350 Million FinancingApril 14, 2026 | quiverquant.comQGalera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private PlacementApril 14, 2026 | globenewswire.comSee More Headlines GRTX Stock Analysis - Frequently Asked Questions How have GRTX shares performed this year? Galera Therapeutics' stock was trading at $0.0220 at the beginning of 2026. Since then, GRTX stock has increased by 354.5% and is now trading at $0.10. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.15. When did Galera Therapeutics IPO? Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Verastem (VSTM) and Alerian MLP ETF (AMLP). Company Calendar Last Earnings11/10/2021Today6/04/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRTX CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.64 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.08 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-99.34% Debt Debt-to-Equity RatioN/A Current Ratio9.74 Quick Ratio9.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.41) per share Price / Book-0.04Miscellaneous Outstanding Shares160,430,000Free Float47,375,000Market Cap$16.04 million OptionableOptionable Beta2.64 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:GRTX) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredA New Approach to Affordable Housing75% of U.S. households cannot afford a median-priced new home. BOXABL's factory-built, foldable homes are desi...BOXABL | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredMusk is burning $2.5 billion a quarter on AI. One company holds the key.SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not softw...Behind the Markets | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts